Download PDF
Thromb Haemost 1991; 65(05): 578-580
DOI: 10.1055/s-0038-1648193
Original Article
Schattauer GmbH Stuttgart

Thromboxane Responsiveness of Dog Platelets Is Inherited as an Autosomal Recessive Trait

Gerhard J Johnson
The Hematology/Oncology Section, Veterans Affairs Medical Center and Medical Genetics Division, Department of Medicine, University of Minnesota, Minneapolis, MN, U.S.A.
,
Linda A Leis
The Hematology/Oncology Section, Veterans Affairs Medical Center and Medical Genetics Division, Department of Medicine, University of Minnesota, Minneapolis, MN, U.S.A.
,
Richard A King
The Hematology/Oncology Section, Veterans Affairs Medical Center and Medical Genetics Division, Department of Medicine, University of Minnesota, Minneapolis, MN, U.S.A.
› Author Affiliations
Further Information

Publication History

Received 21 September 1990

Accepted after revision 14 December 1990

Publication Date:
24 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

Most mongrel dogs have platelets that form thromboxane A2 (TXA2) from exogenous arachidonate, but they fail to aggregate or secrete in response to it. In contrast to these TXA2 insensitive (TXA2-) platelets, some dogs have TXA2 sensitive (TXA2+) platelets that aggregate and secrete when stirred with arachidonate. To evaluate the possible genetic basis for this difference, we carried out seven matings of mongrel dogs that yielded 48 viable offspring. Four matings of dogs with TXA2- platelets (presumed genotype TT) including 2 back-crosses, produced 32 pups with TXA2- (TT) platelets and 0 pups with TXA2+ platelets. A cross between a male with TXA2+ platelets (presumed genotype tt) and a female with TXA2+ (tt) platelets yielded 9 offspring with TXA2+ (tt) platelets and 0 with TXA2- platelets. Crossing a male presumed homozygous (TT) for TXA2- platelets with a female with TXA2+ (tt) platelets produced 2 pups with TXA2- (Tt) platelets and 0 pups with TXA2+ (tt) platelets. The same female with TXA2+ platelets crossed with a male presumed to be heterozygous (Tt) for TXA2- platelets yielded 2 pups with TXA2+ (tt) platelets and 3 pups with TXA2- (Tt) platelets. Segregation analysis of these data supports the hypothesis that the ability of dog platelets to aggregate and secrete in response to TXA2 is inherited as an autosomal recessive trait.

 

  • References

  • 1 Chignard M, Vargaftig B. Dog platelets fail to aggregate when they form aggregating substances upon stimulation with arachidonic acid. Eur J Pharmacol 1976; 38: 7-18
    CrossrefPubMedSearch in Google Scholar
  • 2 Chignard M, Vargaftig BB. Synthesis of thromboxane A2 by nonaggregating dog platelets challenged with arachidonic acid or with prostaglandin H2 . Prostaglandins 1977; 14: 222-240
    CrossrefPubMedSearch in Google Scholar
  • 3 Charo IF, Feinman RD, Detwiler TC, Smith JB, Ingerman CM, Silver MJ. Prostaglandin endoperoxides and thromboxane A2 can induce platelet aggregation in the absence of secretion. Nature 1977; 269: 66-69
    CrossrefPubMedSearch in Google Scholar
  • 4 Johnson GJ, Leis LA, Rao GHR, White JG. Arachidonate-induced platelet aggregation in the dog. Thromb Res 1979; 14: 147-154
    CrossrefPubMedSearch in Google Scholar
  • 5 Johnson GJ, Rao GHR, Leis LA, White JG. Effect of agents that alter cyclic AMP on arachidonate-induced platelet aggregation in the dog. Blood 1980; 55: 722-729
    PubMedSearch in Google Scholar
  • 6 Clemmons RM, Meyers KM. Acquisition and aggregation of canine blood platelets: Basic mechanisms of function and differences because of breed origin. Am J Vet Res 1984; 45: 137-144
    PubMedSearch in Google Scholar
  • 7 Johnson GJ, Rao GHR, White JG. Platelet dysfunction induced by parenteral carbenicillin and ticarcillin: Studies of the dose-response relationship and mechanism of action in dogs. Am J Pathol 1978; 91: 85-106
    PubMedSearch in Google Scholar
  • 8 Wu KK, LeBreton GC, Tai HH, Chen YC. Abnormal platelet response to thromboxane A2 . J Clin Invest 1981; 67: 1801-1804
    CrossrefPubMedSearch in Google Scholar
  • 9 Lages B, Malmsten C, Weiss HJ, Samuelsson B. Impaired platelet response to thromboxane A2 and defective calcium mobilization in a patient with a bleeding disorder. Blood 1981; 57: 545-552
    PubMedSearch in Google Scholar
  • 10 Samama M, Lecrubier C, Conrad J, Hotchen M, Breton-Gorius J, Vargaftig B, Chignard M, Legarde M, Dechavanne M. Constitutional thrombocytopathy with subnormal response to thromboxane A2 . Br J Haematol 1981; 48: 293-303
    CrossrefPubMedSearch in Google Scholar
  • 11 Hattori A, Takahashi H, Takahashi M, Shibata A, Okuma M. A new familial defect of platelet release mechanism (The intracellular Ca++ transport defect?). Acta Haematol Jpn 1981; 44: 969-972
    PubMedSearch in Google Scholar
  • 12 Okuma M, Takayama H, Uchino H. Subnormal platelet response to thromboxane A2 in a patient with chronic myeloid leukaemia. Br J Haematol 1982; 51: 469-477
    CrossrefPubMedSearch in Google Scholar
  • 13 Ushikubi F, Okuma M, Kanaji K, Sugiyama T, Ogorochi T, Narumiya S, Uchino H. Hemorrhagic thrombocytopathy with platelet thromboxane A2 receptor abnormality: defective signal transduction with normal binding activity. Thromb Haemostas 1987; 57: 158-164
    PubMedSearch in Google Scholar
  • 14 Dunlop PC, Leis LA, Johnson GJ. A canine model of defective thromboxane A2 receptor-Gp interaction. FASEB J 1990 4. A1915
    PubMedSearch in Google Scholar
  • 15 Antiplatelet Trialist’s Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet treatment. Br Med J 1988; 296: 320-331
    CrossrefPubMedSearch in Google Scholar
  • 16 Reilly IAG, FitzGerald GA. Aspirin in cardiovascular disease. Drugs 1988; 35: 154-176
    PubMedSearch in Google Scholar
  • 17 Steering Committee of the Physician’s Health Study Research Group. Final report on the aspirin component of the ongoing physician’s health study. N Engl J Med 1989; 321: 129-135
    CrossrefPubMedSearch in Google Scholar
  • 18 Freeman MB, Sicard GA, Allen BT, Neuberger SM, Mathias CJ, Anderson CB. Endogenous canine thrombogenicity is equally important in vascular graft patency as platelet inhibition. Surg Forum 1986; 87: 453-456
    PubMedSearch in Google Scholar
  • 19 Allen BT, Sicard GA, Mathias CJ, Welch MJ, Clark RE. Platelet deposition on vascular grafts. The accuracy of in vivo quantitation and the significance of in vivo platelet reactivity. Ann Surg 1986; 203: 318-328
    CrossrefPubMedSearch in Google Scholar